middle.news
Prescient Therapeutics Launches $7M Share Purchase Plan to Accelerate PTX-100 Trials
9:29am on Wednesday 2nd of July, 2025 AEST
•
Biotechnology
Read Story
Prescient Therapeutics Launches $7M Share Purchase Plan to Accelerate PTX-100 Trials
9:29am on Wednesday 2nd of July, 2025 AEST
Key Points
SPP aims to raise up to AUD 7 million at $0.04 per share
Shares offered at 16.7% discount to 15-day VWAP and 9.1% discount to closing price
Funds to support Phase 2 clinical trials of PTX-100 for T Cell Lymphoma
Eligible shareholders can subscribe up to $30,000 without brokerage fees
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Prescient Therapeutics (ASX:PTX)
OPEN ARTICLE